MEETING MINUTES

Oregon Drug Use Review / Pharmacy & Therapeutics Committee
Thursday, October 7th, 2021 1:00 - 5:00 PM
Via Zoom webinar

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Cathy Zehrung, RPh; Cat Livingston, MD; Stacy Ramirez, PharmD; Tim Langford, PharmD; Caryn Mickelson, PharmD; Robin Moody, MPH; William Origer, MD

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Brandon Wells; Amanda Parrish, LCSW; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD

Audience: Amy Burns, AllCare CCO; Bill McDougall, Biogen; Brandie Feger, Advanced Health; Camille Kerr, Regeneron; Carly Gostanian, PacificSource; Carmen Oliver, BioHaven; Carrie Johnson, Amgen*; Dave West, United Therapeutics; David Bedich, ParaPro; Jennifer Shear, Teva*; Ann Thomas, OHA Center for Public Health Practice*; Laurie Krekemeyer; Lindsey Walter, Novartis; Lisa Dunn; Lori Howarth, Bayer; Christine Hui, United Therapeutics*; Lynda Finch, Biogen; Margaret Olmon, AbbVie*; Mark Kantor, AllCare Health; Matt Worthy, OHSU; Melissa Snider, Gilead Science; Michael Foster, BMS; Mike Willett, Pfizer; Andrew Seaman, OHSU*; Olaf Reinwald, GBT; Lorren Sandt, Caring Ambassadors*; Peter Barrio, United Therapeutics; Rachel Hartman, IHN CCO; Rick Frees, Vertex; Robert Pearce, Teva; Saghi Maleki, Takeda; Sophia Yun, Janssen; Tiffany Jones, PacificSource; Tina Andrews, Umpqua Health Alliance; Tina Hartman, Jazz Pharmaceuticals; Trent Taylor, JNJ; Venus Holder, Lilly USA; Yuval Zabar, Biogen*; John Clark, UMASS*

(*) Provided verbal testimony
I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:05 p.m., introductions by staff and committee
B. Approval of Agenda
C. Conflict of Interest Declaration – no new conflicts of interest were declared
D. Approval of August 2021 Minutes presented by Roger Citron
   ACTION: Motion to approve, 2nd, all in favor
E. Department Update – Trevor Douglass

II. CONSENT AGENDA TOPICS

A. Oncology Prior Authorization (PA) Updates
   Recommendations:
   - Add the following new FDA-approved antineoplastic agents to Table 1 in the Oncology Agents prior authorization (PA) criteria: Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn); and Welireg™ (belzutifan)
B. Orphan Drug Policy Updates
   Recommendations:
   - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Ryplazim® (plasminogen, human-tvmh) and Rezurock™ (belumosudil mesylate) based on FDA-approved labeling
C. Inhaled Anticholinergic Literature Scan
D. Antiepileptics (non-injectable) Literature Scan
   Recommendations:
   - No PDL changes recommended based on the clinical evidence
   - Evaluate costs in executive session
   ACTION: Motion to approve, 2nd, all in favor

III. PREFERRED DRUG LIST NEW BUSINESS

A. Biologics for Autoimmune Disorders Class Update: Deanna Moretz, PharmD
   Recommendations:
   - Make no changes to the PDL based on the review of recent clinical evidence
   - Rename the class “Targeted Immune Modulators” and modify the PA criteria to include expanded ages and indications
- Modify the “Multiple Sclerosis Oral Agents” PA criteria to include the expanded indication for ozanimod in adults with moderate-to-severe ulcerative colitis
- Evaluate costs in executive session

Public Comment: Maggi Olmon, AbbVie; Carrie Johnson, Amgen

ACTION: Motion to approve, 2nd, all in favor

B. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Class Update: Kathy Sentena, PharmD

Recommendations:
- Make no changes to the PDL based on the review of recent clinical evidence
- Update the PA criteria to clarify the difference between acute (abortive) and prophylactic (preventative) treatment
- Update the recommended drugs for cluster headache, and to
- Evaluate costs in executive session

Public Comment: Jennifer Shear, Teva; Maggi Olmon, AbbVie; Carrie Johnson, Amgen

ACTION: The Committee recommended implementing the proposed recommendations after adding a question to require providers assess for uncontrolled hypertension prior to initiation of therapy for applicable agents - including Aimovig®

Motion to approve, 2nd, All in favor

C. Hepatitis C Direct Acting Antivirals (DAA): Megan Herink, PharmD

Recommendations:
- Update the PA criteria and treatment table to include new pediatric indications and clerical updates
- Evaluate costs in executive session

Public Comment: Maggi Olmon, AbbVie; Ann Thomas, OHA Public Health; Andy Seaman, Old Town Clinic/Central City Concern; Lorren Sandt, Caring Ambassadors

ACTION: The Committee requested staff evaluate financial impacts, search for any new clinical information or data from other state programs who have opened access to consider removal of PA criteria for preferred agents and treatment of acute therapy

Motion to approve, 2nd, All in favor

D. Pulmonary Arterial Hypertension (PAH) Class Update: Sarah Servid, PharmD

Recommendations:
- Make no changes to the PDL based on the review of recent clinical evidence
- Update the PA criteria to include expanded indications
- Evaluate costs in executive session

Public Comment: Christine Hui, United Therapeutics

ACTION: Motion to approve, 2nd, all in favor
E. Alzheimer’s Disease Drug Class Update and New Drug Evaluation: David Engen, PharmD

Recommendations:
- Maintain aducanumab as non-preferred on the PDL
- Implement proposed PA criteria to ensure appropriate use
- Evaluate costs in Executive Session

Public Comment: Yuval Zabar, Biogen

ACTION: The Committee recommended amending question #7 to mirror mild disease, as defined in studies including a Mini-Mental Status Exam (MMSE) between 24-30 and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5, and to modify renewal criteria to prevent continuation of therapy in patients with any evidence of microhemorrhage. The Committee also recommended the OHA consider not covering Aduhelm™ due to its significant toxicity and unproven clinical benefit

Motion to approve, 2nd, All in favor

F. Topical Antiparasitic Agents: Sara Fletcher, PharmD

Recommendations:
- Maintain abametapir as non-preferred on the PDL
- Include ivermectin cream (Soolantra®) in the topical antiparasitic class and designate as non-preferred
- No other changes to the PDL based on recent evidence
- Evaluate costs in executive session

Public Comment: John Clark, UMASS; David Bedich, ParaPro

Motion to Approve, 2nd, all in favor

IV. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; William Origer, MD; Cathy Zehrung, RPh; Cat Livingston, MD; Tim Langford, PharmD; Caryn Mickelson, PharmD; Robin Moody, MPH;

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Brandon Wells; Amanda Parrish, LCSW; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD
V. RECONVENE for PUBLIC RECOMMENDATIONS

A. Inhaled Anticholinergic Literature Scan
   Recommendation: Make Combivent® Respimat® & Incruse® Ellipta® preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

B. Antiepileptics (non-injectable) Literature Scan
   Recommendation: No changes to the PDL are recommended
   ACTION: Motion to approve, 2nd, all in favor

C. Targeted Immune Modulators
   Recommendation: Make Cosentyx® preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

D. CGRP Inhibitors
   Recommendation: Make Aimovig® preferred and Emgality® non-preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

E. Hepatitis C DAAs
   Recommendation: Make branded Epclusa® non-preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

F. PAH Drug Class
   Recommendation: No changes to the PDL are recommended
   ACTION: Motion to approve, 2nd, all in favor

G. Alzheimer’s Disease Drug Class
   Recommendation: Make donepezil, rivastigmine, memantine, and Namzaric® preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

H. Topical Antiparasitic Agents
   Recommendation: Make Soolantral® and Vanalice™ non-preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN